<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21596">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01764412</url>
  </required_header>
  <id_info>
    <org_study_id>2012-A01122-41</org_study_id>
    <nct_id>NCT01764412</nct_id>
  </id_info>
  <brief_title>Study of Serum Hepcidin Rate Variations During Menstrual Cycle</brief_title>
  <acronym>HEPMEN</acronym>
  <official_title>Study of Serum Hepcidin Rate Variations During Menstrual Cycle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepcidin is the major hormone regulating Iron Metabolism. In a normal  organism decrease
      iron stock causes a decrease in hepcidin synthesis thus promoting intestinal absorption of
      iron.

      The interpretation of hepcidin dosage results requires to know the  physiological variations
      of this hormone.

      This study investigate whether there are significant variations in the values of serum
      hepcidin rates during the menstrual cycle in order to make recommendations on the practical
      dosage determination of hepcidin in premenopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepcidin is the major hormone regulating Iron Metabolism. Synthesized primarily by
      hepatocytes, it interacts with the cellular iron exporter ferroportin, causing its
      internalization and preventing the release of iron from enterocytes and macrophages.

      In a normal  organism decrease iron stock causes a decrease in hepcidin synthesis thus
      promoting intestinal absorption of iron.

      Since valid methods for the determination of hepcidin serum rate are available, this dosage
      is increasingly used to diagnosis iron metabolism pathologies, in particular iron overload.
      The interpretation of hepcidin dosage results requires to know  physiological variations of
      this hormone.

      Several works have shown that hepcidin varies according to a circadian cycle, that its
      values differ by sex and, in women, by age. As far as the investigators know, no study has
      focused on possible variations in serum hepcidin rates values during menstrual cycle in
      women. Yet this question seems relevant since it has been shown that during the menstrual
      cycle blood loss can cause significant iron and hemoglobin  variations, which can
      significantly modulate the synthesis of hepcidin.

      This study investigate whether there are significant variations in the values of serum
      hepcidin rates during the menstrual cycle in order to make recommendations on the practical
      dosage determination of hepcidin in premenopausal women.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Serum hepcidin rates variations during the menstrual cycle</measure>
    <time_frame>During the menstrual cycle (see description)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time frame : depending on the calendar day of D1 as the following calendars (D1: first day after periods beginning)
D1 occurring on Monday : D1, D3, D4, D8, D15, D26
D1 occurring on Tuesday : D1, D2, D4, D7, D11, D28
D1 occurring on Wednesday : D1, D2, D6, D7, D13, D28
D1 occurring on Thursday : D1, D2, D5, D6, D13, D28
D1 occurring on Friday :  D1, D4, D5, D6, D11, D27
D1 occurring on Saturday : D3, D4, D5, D12, D20, D27
D1 occurring on Sunday :  D3, D4, D5, D12, D19, D26</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seric iron</measure>
    <time_frame>During the menstrual cycle (see description)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time frame : depending on the calendar day of D1 as the following calendars (D1: first day after periods beginning)
D1 occurring on Monday : D1, D3, D4, D8, D15, D26
D1 occurring on Tuesday : D1, D2, D4, D7, D11, D28
D1 occurring on Wednesday : D1, D2, D6, D7, D13, D28
D1 occurring on Thursday : D1, D2, D5, D6, D13, D28
D1 occurring on Friday : D1, D4, D5, D6, D11, D27
D1 occurring on Saturday : D3, D4, D5, D12, D20, D27
D1 occurring on Sunday : D3, D4, D5, D12, D19, D26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transferrin saturation</measure>
    <time_frame>During the menstrual cycle (see description)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time frame : depending on the calendar day of D1 as the following calendars (D1: first day after periods beginning)
D1 occurring on Monday : D1, D3, D4, D8, D15, D26
D1 occurring on Tuesday : D1, D2, D4, D7, D11, D28
D1 occurring on Wednesday : D1, D2, D6, D7, D13, D28
D1 occurring on Thursday : D1, D2, D5, D6, D13, D28
D1 occurring on Friday : D1, D4, D5, D6, D11, D27
D1 occurring on Saturday : D3, D4, D5, D12, D20, D27
D1 occurring on Sunday : D3, D4, D5, D12, D19, D26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum transferrin</measure>
    <time_frame>During the menstrual cycle (see description)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time frame : depending on the calendar day of D1 as the following calendars (D1: first day after periods beginning)
D1 occurring on Monday : D1, D3, D4, D8, D15, D26
D1 occurring on Tuesday : D1, D2, D4, D7, D11, D28
D1 occurring on Wednesday : D1, D2, D6, D7, D13, D28
D1 occurring on Thursday : D1, D2, D5, D6, D13, D28
D1 occurring on Friday : D1, D4, D5, D6, D11, D27
D1 occurring on Saturday : D3, D4, D5, D12, D20, D27
D1 occurring on Sunday : D3, D4, D5, D12, D19, D26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum ferritin</measure>
    <time_frame>During the menstrual cycle (see description)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time frame : depending on the calendar day of D1 as the following calendars (D1: first day after periods beginning)
D1 occurring on Monday : D1, D3, D4, D8, D15, D26
D1 occurring on Tuesday : D1, D2, D4, D7, D11, D28
D1 occurring on Wednesday : D1, D2, D6, D7, D13, D28
D1 occurring on Thursday : D1, D2, D5, D6, D13, D28
D1 occurring on Friday : D1, D4, D5, D6, D11, D27
D1 occurring on Saturday : D3, D4, D5, D12, D20, D27
D1 occurring on Sunday : D3, D4, D5, D12, D19, D26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepcidin / ferritin rate</measure>
    <time_frame>During the menstrual cycle (see description)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time frame : depending on the calendar day of D1 as the following calendars (D1: first day after periods beginning)
D1 occurring on Monday : D1, D3, D4, D8, D15, D26
D1 occurring on Tuesday : D1, D2, D4, D7, D11, D28
D1 occurring on Wednesday : D1, D2, D6, D7, D13, D28
D1 occurring on Thursday : D1, D2, D5, D6, D13, D28
D1 occurring on Friday : D1, D4, D5, D6, D11, D27
D1 occurring on Saturday : D3, D4, D5, D12, D20, D27
D1 occurring on Sunday : D3, D4, D5, D12, D19, D26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepcidin / transferrin saturation rate</measure>
    <time_frame>During the menstrual cycle (see description)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time frame : depending on the calendar day of D1 as the following calendars (D1: first day after periods beginning)
D1 occurring on Monday : D1, D3, D4, D8, D15, D26
D1 occurring on Tuesday : D1, D2, D4, D7, D11, D28
D1 occurring on Wednesday : D1, D2, D6, D7, D13, D28
D1 occurring on Thursday : D1, D2, D5, D6, D13, D28
D1 occurring on Friday : D1, D4, D5, D6, D11, D27
D1 occurring on Saturday : D3, D4, D5, D12, D20, D27
D1 occurring on Sunday : D3, D4, D5, D12, D19, D26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepcidin / serum iron rate</measure>
    <time_frame>During the menstrual cycle (see description)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time frame : depending on the calendar day of D1 as the following calendars (D1: first day after periods beginning)
D1 occurring on Monday : D1, D3, D4, D8, D15, D26
D1 occurring on Tuesday : D1, D2, D4, D7, D11, D28
D1 occurring on Wednesday : D1, D2, D6, D7, D13, D28
D1 occurring on Thursday : D1, D2, D5, D6, D13, D28
D1 occurring on Friday : D1, D4, D5, D6, D11, D27
D1 occurring on Saturday : D3, D4, D5, D12, D20, D27
D1 occurring on Sunday : D3, D4, D5, D12, D19, D26</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Healthy Women</condition>
  <arm_group>
    <arm_group_label>Healthy women</arm_group_label>
    <description>Non interventional</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Hepcidin Serum iron Transfferin saturation Serum transfferin Serum ferritin
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy women
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Woman aged over 18 and under 45 years,

          -  Having given free and informed written consent,

          -  Having regular cycles (defined by a constant interval between periods of 28 to 30
             days),

          -  Having periods for a duration of 4 + / - 1 days

          -  Not using contraception or using oral oestroprogestative contraception.

        Exclusion Criteria:

          -  Contraceptive IUD

          -  Metrorrhagia

          -  Pregnancy,

          -  BMI under 18 kg / m² and above 30 kg / m²,

          -  Presence of at least one of the following abnormalities in serum iron balance :
             Hemoglobin &lt;11.5 g / dl, transferrin saturation under 15% or greater than 50%, serum
             ferritin under 15μg / l or greater than 150 µg / l

          -  Active smoking or quit within the last 6 months

          -  Drinking more than 20 g of alcohol per day ,

          -  Iron supplementation or blood transfusion within 12 months before inclusion

          -  Blood donation within 3 months before inclusion,

          -  Stay in altitude&gt; 1500 m in the previous month before inclusion

          -  Chronic inflammatory disease,

          -  Incapable people over 18 (judicial protection, guardianship) and persons deprived of
             their liberty.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice lainé, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Rennes - CIC INSERM 0203</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabrice Lainé, MD</last_name>
    <phone>2 99 28 92 01</phone>
    <phone_ext>+33</phone_ext>
    <email>fabrice.laine@chu-rennes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <state>Bretagne</state>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice Lainé, MD</last_name>
      <phone>299289201</phone>
      <phone_ext>+33</phone_ext>
      <email>fabrice.laine@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Fabrice Lainé, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karine Lacut, MDPhD</last_name>
      <phone>2 98 34 50 00</phone>
      <phone_ext>+33</phone_ext>
      <email>cic_centre_ressources_methodologique@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Karine Lacut, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvie Sacher-Huvelin, MD</last_name>
      <phone>2.40.08.31.52</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Sylvie Sacher-Huvelin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chru Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valérie Gissot, MD</last_name>
      <phone>2 34 37 96 53</phone>
      <phone_ext>+33</phone_ext>
      <email>valerie.gissot@univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Valérie Gissot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 27, 2014</lastchanged_date>
  <firstreceived_date>January 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy women</keyword>
  <keyword>Menstrual cycle</keyword>
  <keyword>Hepcidin</keyword>
  <keyword>Seric iron</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepcidin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
